Our observations that SR141716A evoked insulin release at 2 mM glucose are in agreement with the requirement for some rimonabant-treated patients to reduce their anti-diabetic medication [15], and induction of hypoglycaemic episodes by rimonabant in some insulin-treated patients with type 2 diabetes [44]. This evidence concerns the gene INS and type 2 diabetes mellitus.